Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a...
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. In particular, the stock is 'expensive' on EV/EBITDA.
Target Price
The average target price of SLGL is 110 and suggests 31% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
Buy
Sell